Pfizer Saudi Limited signed an exclusive commercial agreement with Tabuk Pharmaceuticals. The deal will permit Pfizer to advertise and promote branded and high-value generic drugs, such as medicines that provide treatment for kidney dialysis, kidney transplant, urology, and the central nervous system. This agreement is part of a larger Vision 2030 effort to strengthen local manufacturing capabilities. Pfizer started production at a $50 million plant in Saudi Arabia in January.
Pfizer Signs Commercial Agreement
You also might be interested in
The Capital Market Authority’s (CMA) Chairman, Mr. Mohammed El Kuwaiz,[...]
by H. Delano Roosevelt President & CEO, U.S.-Saudi Business Council[...]
Saudi Arabia Macroeconomic Developments Saudi Arabia reported a Q3[...]